1. Home
  2. LNT vs ILMN Comparison

LNT vs ILMN Comparison

Compare LNT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alliant Energy Corporation

LNT

Alliant Energy Corporation

HOLD

Current Price

$65.52

Market Cap

16.8B

Sector

Utilities

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$128.90

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNT
ILMN
Founded
1917
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.8B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
LNT
ILMN
Price
$65.52
$128.90
Analyst Decision
Buy
Hold
Analyst Count
8
15
Target Price
$69.38
$114.93
AVG Volume (30 Days)
2.1M
1.5M
Earning Date
11-06-2025
10-30-2025
Dividend Yield
3.10%
N/A
EPS Growth
23.58
N/A
EPS
3.18
4.46
Revenue
$4,274,000,000.00
$4,288,000,000.00
Revenue This Year
$7.01
N/A
Revenue Next Year
$4.72
$2.08
P/E Ratio
$20.59
$28.91
Revenue Growth
7.77
N/A
52 Week Low
$56.30
$68.70
52 Week High
$69.75
$153.06

Technical Indicators

Market Signals
Indicator
LNT
ILMN
Relative Strength Index (RSI) 36.28 66.70
Support Level $67.10 $124.27
Resistance Level $69.50 $129.72
Average True Range (ATR) 0.95 3.90
MACD -0.32 -0.41
Stochastic Oscillator 6.35 77.82

Price Performance

Historical Comparison
LNT
ILMN

About LNT Alliant Energy Corporation

Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: